CDK5 and ischemia: Although it has been postulated that pilot inhibitors of Cdk5, such as enantiomers of roscovitine, display improved BBB permeability and functional protection following ischemia, Cdk5 site-directed decreases in phosphorylation stoichiometry have not been clearly shown (Menn et al., 2010).